Prescribing overview
Local treatment for selected non-metastatic canine mast cell tumors.
Tumor destruction leaves a wound. Extensive tissue loss and life-threatening mast cell degranulation are important labeled risks.
Key prescribing checks
- Read the product-specific safety section and monitoring plan before selecting a treatment.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary labelNon-metastatic cutaneous mast cell tumors; subcutaneous mast cell tumors at or below the elbow/hock
Stage the tumor and confirm its location before selection.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Local cellular injury, inflammation and tumor-vessel disruption produce tumor necrosis.
Absorption, distribution, metabolism and elimination
Systemic exposure after intratumoral treatment is variable; local administration does not eliminate systemic risk.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Stelfonta
US veterinary label; Intratumoral injection.
Contraindications · when not to use
- Do not inject subcutaneous mast cell tumors above the elbow or hock.
Precautions & monitoring
- Not intended for metastatic tumors. Evaluate wound-healing risks and mucocutaneous sites. Avoid injection beyond tumor margins.
Selected product scope; does not establish suitability for other species, routes or formulations.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Pain, edema, bruising, cellulitis, extensive wounds and severe systemic degranulation can occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this reference. The veterinarian must select the exact product-label protocol for the patient, indication and route; this entry does not enable an automatic dose.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Stelfonta
US veterinary label; Intratumoral injection.
- The label requires a corticosteroid plus H1 and H2 blockers; these are protective co-medications, not optional duplicate treatments.
Monitoring
Assess systemic degranulation after treatment and wound progress until healed; severe pain, swelling or breathing changes need urgent reassessment.
Client counseling
Give every prescribed companion medicine. Prevent licking; wear gloves for wound care and report worsening illness.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Single-use vial; follow current label refrigeration and hazardous-handling instructions. Accidental self-injection can cause severe wounds.
Brands, formulations & ingredient identity
Active ingredients
Tigilanol tiglate
An intratumoral oncology product; not a routine systemic injection.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Stelfonta
- Formulation
- Intratumoral injection
- Label / product scope
- Dogs
Stage the tumor and confirm its location before selection.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →